Compare Vir Biotechnology Inc. Common Stock (VIR) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vir Biotechnology Inc. Common Stock vs Vanguard High Dividend Yield ETF — how do they compare? Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B), while Vanguard High Dividend Yield ETF trades at $159.04 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 56× Vir Biotechnology Inc. Common Stock's market cap, and Vanguard High Dividend Yield ETF is more actively traded (834,323 versus 1,782,836). Which is the better fit depends on your goals — on Pluang, investors hold Vir Biotechnology Inc. Common Stock for 0 Days and Vanguard High Dividend Yield ETF for 140 Days on average.
| VIR | VYM | |
|---|---|---|
Market Cap | $1.80B | $100.80B |
Volume | 1,782,836 | 834,323 |
Sector | Health | — |
52-Week High | $11.78 | $167.03 |
52-Week Low | $5.12 | $138.43 |
Typical Hold Time | 0 Days | 140 Days |
Enterprise Value | $1.36B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VYM trades at $159.11, down slightly by 0.08% today, with a bullish technical signal from moving averages despite neutral oscillators. The ETF maintains strong sector diversification and a 2.42% dividend yield, though recent news highlights competition from alternatives like SCHD and IDV. Support levels are clustered around $157-158, with resistance at $160-161.
Outlook remains mixed; VYM offers steady income but faces pressure from higher-yielding or better-performing peers. Key risks include dividend cuts in holdings like Intel and Walgreens, while institutional sentiment leans cautious due to moderate growth prospects versus competing ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vir Biotechnology Inc. Common Stock
Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
